医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

在日本实施的自体免疫细胞疗法在GN Corporation技术转让后帮助Vinmec医院治疗越南河内的癌症患者

2022年10月11日 PM04:09
このエントリーをはてなブックマークに追加


 

东京

(美国商业资讯)–自体免疫增强细胞疗法(AIET)利用个人自身的免疫细胞、自然杀伤细胞(NK)和T细胞治疗癌症。该疗法与传统的化疗、放疗和手术联用,已在日本长时间实施。在GN Corporation进行技术转让后,越南河内的Vinmec医院如今也提供这种疗法。来自周边国家的癌症患者当前正前往Vinmec医院接受这种治疗。自体免疫细胞疗法受日本再生医学法规的监管。该疗法使用实验室扩增的自体免疫细胞,没有采用动物蛋白或基因操作。

本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20221002005094/zh-CN/

NK cells and T-cells in vitro culture method, without feeder cells or animal serum or genetic manipulation, for immune-cell therapy to cancer patients developed and practiced in Japan was tech-transferred to Vinmec Hospital, Hanoi, Vietnam, which was accomplished in phases viz., (i) Cell processing facility infrastructure and equipment advisory, (ii) Training of biotechnologists from Vietnam in Japan, (iii) On-site, technical support in Vinmec hospital lab by Japanese experts (iv) Educational seminars to physicians, oncologists and (v) Interaction with regulatory authority in Japan, the PMDA and MHLW; spearheaded by GNC Japan. Immune-cell therapy with Thermotron RF8-EX radiofrequency hyperthermia, when added to conventional cancer treatment, yields increase in survival of cancer patients. These safety proven treatments practiced for long in Japan to manage most of the solid tumours are of interest to many cancer hospitals overseas to add them to their existing oncology services. (Graphic: Business Wire)

NK cells and T-cells in vitro culture method, without feeder cells or animal serum or genetic manipulation, for immune-cell therapy to cancer patients developed and practiced in Japan was tech-transferred to Vinmec Hospital, Hanoi, Vietnam, which was accomplished in phases viz., (i) Cell processing facility infrastructure and equipment advisory, (ii) Training of biotechnologists from Vietnam in Japan, (iii) On-site, technical support in Vinmec hospital lab by Japanese experts (iv) Educational seminars to physicians, oncologists and (v) Interaction with regulatory authority in Japan, the PMDA and MHLW; spearheaded by GNC Japan. Immune-cell therapy with Thermotron RF8-EX radiofrequency hyperthermia, when added to conventional cancer treatment, yields increase in survival of cancer patients. These safety proven treatments practiced for long in Japan to manage most of the solid tumours are of interest to many cancer hospitals overseas to add them to their existing oncology services. (Graphic: Business Wire)

AIET和热疗的益处:据报道,传统的治疗方案联用免疫细胞疗法可以提高癌症患者的生存率,而由于癌细胞在42℃的高温下容易受损,日本开发的热疗系统可靶向癌细胞,进一步改善癌症治疗的效果。GNC日本公司正在与Thermotron的制造商Yamamoto Vinita合作,向海外医院推广这些附加性的癌症疗法。Thermotron是日本批准的第一个治疗恶性肿瘤的热疗设备,至今已安装在六个国家的300多家医院。最新的Thermotron-RF8-EX版是一个独立的系统,支持8MHZ的射频,使用不同大小的电极组合来治疗除眼睛和大脑以外的整个身体的表层和深层实体瘤。

Thermotron RF8-EX的显著特点:

  • 增强放化疗有益效果
  • 提高免疫力和癌症患者生活质量
  • 没有辐射,因此不需要任何屏蔽措施
  • 能轻易提高目标病变区域的温度
  • 自1980年以来,在300多家癌症医院拥有安全记录

提供这些癌症疗法的日本医院接受来自国外的病人。最近,海外癌症医院开始表现出在其现有的肿瘤临床治疗服务中增加这两种疗法的兴趣。

关于GN Corporation通过跨学科互动为日本技术增值、开发全新医疗解决方案和全球传播方面所获得的成就,日本政府在日本首相办公室的官方YouTube频道JETRO投资日本门户网站以及日本政府向彭博社赞助的专题报道中予以了介绍。

免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

在 businesswire.com 上查看源版本新闻稿: https://www.businesswire.com/news/home/20221002005094/zh-CN/

CONTACT

Samuel JK Abraham

info@gncorporation.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
  • 知临集团宣布发行 2023 年到期的 300 万美元可转换票据
  • ZCGの関連会社がユニバーサル・マリン・メディカル・サプライ・インターナショナルを買収
  • BiomeBank Continues Growth Trajectory With Over $10M Capital Raise
  • Medidata推出全新原生应用程序“myMedidata”,加速研究启动并提升患者体验